Bringing Innovative Solutions to Health Practitioners: Moleac

Moleac is a biopharmaceutical company headquartered in Singapore. Its operations and research are located in Biopolis, a world-class purpose-built a complex for biomedical sciences research. It brings together Asian and Western medicines by identifying promising medicine discovered in China and developing them into Western mainstream medicine. Conversely, Moleac develops and markets in Asia innovative technologies and medical products that are in-licensed from Europe.

The Vision

CEO, David Picard on Moleac’s Vision:

“We are committed to helping patients and their families reconnect with their lives.

We address unmet needs of patients suffering a loss of brain functions after brain injuries or neurodegenerative diseases. Our focus is to help them regain and maintain independence. We select scientifically proven natural compounds and formulations with origins in traditional medicine, establish their clinical properties and make them available internationally.”

Innovation to Reconnect: NeuroAiD

A Natural Product

NeuroAiD is a natural product combining several active ingredients including nine herbal extracts in the form of capsules. The development of NeuroAiD was aimed at helping sufferers achieve a faster and fuller recovery after a Brain Injury (Stroke, Traumatic Injury) and both the pharmacology and the clinical research have been structured for that.

NeuroAiD is available in about 30 markets; under local regulations, its status varies from Food Supplement to Drug, and its status varies from country to country, and so does the indication for which it is recommended and approved. As an illustration, when the status is that of a food supplement, no reference to Stroke or disease is permitted in the local general communication.

With Multimodal Mechanism of Action

Its multi-ingredient composition gives NeuroAiD a multimodal mechanism of action enhancing the natural brain self-repair process by stimulating

• Neuroplasticity
• Neurogenesis
• Angiogenesis

These properties give the possibility to repair the damaged areas to regain cognitive and functional capabilities.

NeuroAiD™ II & NurAiD™ II (MLC 901)

NeuroAiD™ II & NurAiD™ II (MLC 901) correspond to the simplified formula of NeuroAiD™ (MLC 601), containing only the main 9 herbal ingredients from the original formula which was shown in 2010 to be equivalent to the original formulae. NeuroAiD II was first launched in 2011 commercially. In 2018, Moleac will be phasing out MLC601 and replacing it progressively in all markets with MLC 901. All recent research is also conducted on MLC901

Indeed, the need for the non-herbal ingredients in MLC601, such as crushed dried scorpions, leech or antelope horn, however, was questioned as the rationale for their role was not obvious beyond traditional beliefs. MLC901 (NeuroAiD II, Moleac Pte. Ltd, Singapore), was therefore developed consisting of only the nine herbal ingredients that are present in MLC601. MLC901 has been demonstrated to be pharmacologically equivalent to MLC601 with similar neuroprotective and neurorestorative properties in nonclinical studies. In addition to presenting the same benefits and safety profile, the simplified formulation has the advantages of reduced variability, avoidance of unnecessary animal slaughter.

Multi-Modal Approach To Treat Brain Injuries

Identifying the Multiple and Complex Mechanisms of Brain Damages and Repair

Advances in research in the field of brain injury, including stroke, trauma, and global ischemia, have never been more exciting and encouraging to identify novel effective treatments. Neuroscientists have elucidated cellular and molecular mechanisms involved in damages and neurorepair, representing attractive targets to reduce the extent of damage and to enhance remodeling.

Crossing the Conventional Therapeutic Approach to Answer the Complexity of Stroke

Stroke is a complex pathology. Treatment encompasses prevention, acute cares, and recovery. While several therapeutic strategies are available to prevent the occurrence of a secondary ischemic episode, acute therapeutic possibilities are limited to revascularization and rehabilitation management. Thus health professionals are facing a therapeutic gap regarding post-stroke recovery.

The conventional approach was to develop one molecule to target one specific process in the pathway of one particular disease. This approach was hampered by consecutive failures of multiple clinical trials to prove benefits of potential treatments. With NeuroAiD™, Moleac took a different approach.

Accelerated Development Model for NeuroAiD™

Moleac takes on a multi-modal approach for drug development. This approach gives the company the possibility to support and enhance multiple natural processes taking place into the brain and representing its ability to protect it and to recover after an injury.

Moleac model includes 4 steps:

• Selecting ingredients for their pharmacological effects in validated in-vitro and in-vivo models
• Conducting controlled clinical trials to establish safety and efficacy
• Developing, manufacturing and marketing an optimized formula
• Establishing the molecular basis of efficacy to develop a simplified formula

For post-stroke recovery, Moleac have identified a complex formula combining natural ingredients and developed it following international standards of manufacturing and quality control testing. NeuroAiD™ has shown properties of neuroprotection and neuroplasticity affecting multiple pharmacological pathways in rodent models, and animal/human cells cultures. Clinical trials in post-stroke patients have confirmed NeuroAiD™ properties and established its safety and efficacy in stroke survivors by improving their chances of achieving functional independence over the long-term through an increased neurological recovery.

Meet the Leader

David Picard, Chief Executive Officer: David co-founded Moleac and has been serving as CEO since. Prior to founding Moleac, David has spent ten years at the Boston Consulting Group (“BCG”) where he was a member of the worldwide Health Care Practice Area. He has worked both in Europe and in Asia. He has extensive experience in working in China and in Korea.

David graduated from the two top engineering schools in France, Ecole Polytechnique, and Ecole Nationale Supérieure des Mines de Paris, where he majored in mathematics and economics. David also holds a French degree (“DESS”) in business law.

“We are all diverse, with our own personality, culture, background, but we are together as one team providing new answers toward medical gaps and help those who suffer around the globe. This is who we are, across our functions and locations, we are committed to helping patients and their families reconnect with their lives.”